By Aimee Green email@example.com
The parents of a 2-year-old girl who died, reportedly after a heater in their apartment raised the temperature in the girl’s room to a lethal level, filed an $8 million lawsuit this week.
Taqwa Dakhlalla was a healthy little girl but died last Dec. 11 when the heater and the thermostat in her room malfunctioned as she slept, said Jane Paulson, a Portland attorney representing the girl’s estate. Taqwa’s parents — Janna Walton and Abdullah Dakhlalla — found their daughter the next morning in her crib, Paulson said. The lawsuit faults apartment owners Cathedral Park Investments LLC and the apartment management company Gordon Properties Inc. The family’s apartment was in the 8300 block of North Willamette Boulevard.
Carl Rodrigues, a Portland attorney representing the defendants, said much more investigation into the incident needs to be done, but so far he’s found no liability on the part of his clients.
Taqwa’s family also recently filed a lawsuit in Washington against the company, Cadet heaters, that’s believed to have distributed the heater, Paulson said.
The Oregon Health Authority listed Taqwa’s cause of death as hyperthermia, or overheating.
In April, the Multnomah County District Attorney’s Office sent Gordon Properties a letter stating that the thermostat in Taqwa’s room was reportedly set to 62 degrees, but the temperature next to the girl’s crib reached 90 degrees or higher as the heater apparently kept running. The DA’s office said that during testing after the girl’s death, the air blowing from the heater hovered between 110 and 115 degrees, and spiked once to 200 degrees. The DA’s office asked Gordon Properties to inspect the wall heater in the apartment and any other apartments with similar heaters. The letter stated that if necessary, the company should replace the heaters.
Taqwa was an only child, although her mother gave birth to a second child in September.
Walton has posted several photos, videos and entries about the couple’s enormous loss. “Today marks 6 months without your little giggles, 26 weeks without our cuddle sessions, 182 days without our countless kisses but it also marks 4380 hours of you still making your baba’s life and mines ceaselessly better,” Walton wrote in one post. “I love you so much, Taqwa,” Walton continued. “Mommy has to rediscover herself because you were all she ever wanted.”
The lawsuit was filed Monday in Multnomah County Circuit Court.
HARTFORD, Conn. (Reuters) – A lawyer for families who lost loved ones in the 2012 Sandy Hook school shooting told Connecticut’s highest court on Tuesday that Remington Outdoor Co. should be held responsible because its military-themed marketing was designed to appeal to young men like killer Adam Lanza. “They knew they were hitting their mark and Lanza was responding to their marketing,” said lawyer Joshua Koskoff. Lanza, 20, used a Remington AR-15 Bushmaster rifle, a semi-automatic civilian version of the U.S. military’s M-16, to kill 20 school children between the ages of 6 and 7, as well as six adult staff members, at Sandy Hook Elementary School in Newtown, Connecticut, on Dec. 14, 2012. He then killed himself.
Following the conclusion Tuesday’s arguments, the Connecticut Supreme Court will now decide whether the families of nine of the victims and one survivor can proceed with a trial seeking to hold Remington, along with a gun wholesaler and local retailer, responsible for the carnage based on its marketing. A representative for the court declined to say when it would rule.
The families are advancing a somewhat novel legal argument in hopes of overcoming a federal law enacted by U.S. Congress in 2005 to shield gun manufacturers from liability for how their products are used. Remington’s lawyer, James Vogts, told the Connecticut court that the families’ claims, first filed in 2014, are barred by the 2005 law. “What happened in the school that morning was horrific,” Vogts said. “But no matter how much we wished those children and teachers were still alive, the law needs to be applied.” A lower court judge agreed with the gun maker and dismissed the families’ lawsuit in 2016. But the Connecticut Supreme Court agreed to hear the case a week after the families filed their first appeal.
The packed courtroom in Hartford, Connecticut, included many of the victims’ family members. Ian Hockley, who lost his 6-year-old son, Dylan, in the shooting, told reporters after the proceeding that families were “running out of patience” over the gun maker’s ability to escape liability. “But we have not lost one ounce of confidence in the validity of our case,” he said.
The families claim Remington and the other defendants “extolled the militaristic and assaultive qualities” of the AR-15, advertising the rifle as “mission-adaptable” and “the ultimate combat weapons system” in a deliberate pitch to a demographic of young men fascinated by the military.
The families said Lanza was part of that demographic and cited media reports saying he previously expressed a desire to join the army. The rifle was bought by Lanza’s mother, whom he also killed, as a gift for him or for the two of them to share, the lawsuit claims. The families’ argument is based on the legal doctrine of negligent entrustment, in which a product is carelessly sold or given to a person at high risk of using it in a harmful way. Negligent entrustment is specifically excepted from the 2005 gun maker shield laws.
The argument has historically been used where someone lends a car to a high-risk driver who goes on to cause an accident. It has met with some success in lawsuits against gun shop owners, but legal experts said it has never been used before to target a manufacturer.
David Studdert, a Stanford law professor, said on Monday he thought negligent entrustment was a tough argument for the families to make because it has traditionally involved someone having direct knowledge that another person poses a risk.
If the Sandy Hook families are successful, Timothy Lytton, a law professor at Georgia State University, said on Monday he would expect the U.S. Supreme Court to take up the case.
(Reporting by Tina Bellon; Editing by Anthony Lin and Matthew Lewis)
The rights of every American citizen depend on the regulation of the conduct of insurance companies. The relationship between an insurer and an insured is asymmetric, in that the insurer is the powerful one, and the insured is the less powerful party, who needs to be able to rely on their insurance company to act fairly.
The insurance behemoths such as State Farm, Allstate, Progressive, GEICO, Liberty Mutual, etc., are multi-billion dollar companies that have a drastic advantage when dealing with their insureds. Besides the obvious advantage that most insureds will not have the monetary resources to fight their insurance company, most will not have the actual knowledge about what claims they need to bring, when their claim needs to be brought, and what amount money their claim is worth. The insurance company shares both this financial advantage and the analytical advantage.
Insurance companies are for-profit entities and they need to earn money to stay in business. They can do so by properly investing the income they earn off of premiums. They can do so in choosing to write policies only to some people who do not present much risk, and declining to write policies to others. They can do so by aggressive advertising campaigns promising that they are “on your side” or “you’re in good hands.”
However, there is one place where it is entirely inappropriate for an insurance company to be focused solely on profits. That is claims brought by their own insured under a policy that the insured pays premiums on every month for the right to bring a claim. Why is this so important? It’s because of the commodity that they are selling. A car dealership sells cars. A realtor sells homes. An insurance company sells a promise. The promise is that when you pay for insurance with us, you will have the right to make a legitimate claim under the policy. They will take your claim seriously. They will promptly return your calls and correspondence. They will inform you if you are about to blow a deadline to file a lawsuit or if there is a claim that you are able to make that you are unaware of as the uninformed insured. They will make a settlement that is in the realistic range with efforts to avoid drawn-out litigation.
If the insurance company has a policy that amounts to aggressively fighting legitimate claim brought by their own insureds, that is not only unethical, it is stealing. The reason why this is stealing is that an insured pays every month for the right to assert such a claim. The insureds are not paying for a ruthless opponent who will drag things out for years, try to deny coverage on technicalities, compel litigation, accuse them of lying, etc. If an insurance company acts this way, the insured is paying something and getting nothing in return.
Bad faith statutes
Some states have laws that allow an insured to sue his own insurance company for bad faith for a variety of improper conduct by the insurer. The punishment for acting in bad faith may involve the imposition of punitive damages, the payment of attorney’s fees, the payment of the costs of a party, and other damages. The reason that it is so important to have such a statute is that it helps to even out the power imbalance between an insurer and an insured. Only when the prospect being slammed with a bad faith verdict and paying punitive damages is a possibility does the insurer understand that the best financial decision that they can make is to treat their insured fairly.
Think about this. Let’s say you have collision coverage on your vehicle. There is $10,000 of damage caused to the vehicle by an accident, and you make a claim under your policy to have the vehicle repaired, the same policy that you make payments on every month. Let’s say the insurance company makes an outrageous claim that the damage is unrelated to the accident, or that you failed to mitigate damages or another baseless defense. They decline to pay for your car.
Your only option is to sue your insurance company. However, they have a ton of money, adjusters crunching the analytics, and attorneys on staff who are much more knowledgeable about the court system than you. So what is the plan? It’s time to hire an attorney. But it’s only a $10,000 claim. On a 33-40% plus costs fee, you would only likely get $4,000-$6,000 after your attorney gets paid, roughly half the value of the car. You could pay hourly and get billed $200-$300 per hour. The result would likely be the same. The insured gets a far less than complete recovery, and that’s assuming they can even find a lawyer to handle such a case.
Every state should have a bad faith statute. There should also be a federal bad faith statute so that where you live does not limit your rights against insurance companies. The bad faith statute must provide for punitive damages, attorneys fees, legal costs, and other damages that a court sees fit.
I practice in two states, Pennsylvania and New Jersey. Pennsylvania has a bad faith statute. When an insurer has acted improperly when dealing with my client, the threat of a bad faith lawsuit, or in some cases, the filing of a bad faith lawsuit, has made the insurer back down and do the correct thing, whether that means offering more money on the claim or agreeing that coverage for the loss exists. New Jersey has no such statute. The only bad faith is common law bad faith, which is rarely applied in any case. Thus, in New Jersey, insurance companies can do pretty much whatever they want without the fear of any consequences.
An illustrative case
A case that I had recently was illustrative. The plaintiff suffered a herniated disc with cervical radiculopathy in her neck as a result of a crash in which the tortfeasor crossed the median of a road and hit another car head on, throwing that car into the plaintiff’s car. The only coverage to go after was the plaintiff’s underinsured motorist (UIM) policy. The plaintiff did not desire to file a lawsuit against her insurance company, wishing to settle pre-suit. However, her insurer would not budge above $10,000, an arbitrarily low number.
In all efforts to avoid litigation, we set up a non-binding arbitration hearing under her insurance policy. Written discovery was exchanged prior to the arbitration and the plaintiff submitted to a pre-suit independent medical examination.
The format for the arbitration was both the plaintiff and her insurer selected their own arbitrator and those two arbitrators selected a neutral arbitrator. After deliberating, the arbitrators (even the one hired by the insurance company) returned a unanimous award for $65,000. The defense rejected the award, which is not a big deal in and of itself, given the non-binding nature of the proceeding. The thing that was shady was not that they were unwilling to pay $65,000, it was that they still would not budge above $10,000. Therefore, it was a pointless arbitration, a waste of everyone’s time. The insurance company, from the start, knew that they would only accept the arbitration award if it was some minimal number that was in line with their offer, they would not accept any information that was not compatible with their original analysis.
Baffled by their total unwillingness to negotiate despite the $65,000 award, I called the insurer’s defense lawyer. In the phone call, he conceded that they fight UM and UIM cases very hard because the worst case scenario is that they have to pay the policy limits, and not an award that exceeds the policy, as they would in a third party case. I was shocked by his honesty. What he told me was something that I suspected, that internal policies existed at this insurance giant that says that they fight every case hard.
I filed a lawsuit for UIM benefits under the plaintiff’s policy at this point. During the course of the lawsuit, the insurance giant answered interrogatories accusing my client of causing the accident. As a reminder, the accident was caused by the other driver crossing the median of a road and hitting the car right next to my client’s car. The insurance giant knew that my client did nothing wrong. They knew that no information could possibly arise that could indicate my client had a role in causing the crash. They merely did it to preserve the defense, to be a tough opponent.
I’d had enough, filing a bad faith lawsuit. However, unlike in Pennsylvania where you could litigate a bad faith lawsuit concurrently with the UIM action, in New Jersey, these actions are severed. My bad faith claim was dismissed and I was told that I could refile it after the UIM case was over. As a practical matter, I would have to get a trial verdict that greatly exceeded the offer before I could do anything to punish the insurance company.
The litigation continued. Depositions were taken. Eventually, the court arbitration was scheduled. At this hearing, a court-appointed arbitrator reviewed our packets, heard some brief testimony from my client, and awarded $50,000 in favor of my client.
At this point, it seemed like everything was going to work out. The insurance giant scoffed at the first arbitration award. However now that there was a second arbitration award in the same range, surely the insurance giant would take a second look at this one. Even if they wouldn’t pay the $50,000, they would come to the negotiating table. I was very wrong.
I sent a letter to the defense stating that I would accept the $50,000, even though it was the lower of the two arbitration awards. Not only did the defense appeal, they refused to raise the offer above $10,000. There was nothing to do at this point but to gear up for trial.
The insurance company was going to have to pay their doctor thousands of dollars soon. They would be paying their lawyer thousands of dollars as well for the doctor depositions and trial. Surely this would make them come to the negotiating table. Wrong.
The plaintiff’s doctor testified by videotape. No change in the offer. The defense doctor testified by videotape. No increase in the offer. It had reached the point where there was no doubt whatsoever that the insurance giant had spent more money fighting the case than they had offered in settlement on it. Why would the insurance company want to pay lawyers and doctors instead of their own insured?
My only option is to crush them at trial. A jury hearing that my client’s own insurance company would rather attack her than pay her in a perfectly good case would anger the jurors and get them to award a fair verdict that greatly exceeded the offer. Afterwards, I would pursue the bad faith case and hopefully get a punitive damages award on top of the trial verdict.
Unfortunately, this never happened. In New Jersey, the law dictates that the jury will not hear about insurance, even though the insurance company was the actual party to the case. Instead of trying a case against the insurance giant who would do anything to not pay, I tried a case against the tortfeasor, who had died in the accident.
Several of the jurors, when doing voir dire in the back room, expressed concerns about how this case involves a dead person being sued. I wanted to scream out, “it’s her own insurance company pretending to be a dead guy. They literally will stop at nothing.” However, obviously, I did not do that. That would have been a mistrial.
The defense came up to $15,000 during the trial. They never went higher. My opposing counsel went after my client and her husband extremely aggressively on the stand. My client and her husband did not even wish to sue and it was her insurer who compelled the lawsuit by not negotiating after the arbitration award. My client had never sued anyone else in her entire life before. She had lived a good life. She had never done anything in her life to deserve to be attacked and called a liar on the stand.
The trial concluded. My closing went very well. I hit all my points, showing how frivolous the defense arguments were. I noticed that my client had teared up a little when I walked over to her after finishing the closing. Everything was going to work out. So I thought.
A shocking outcome
The jury went out and deliberated. Liability was stipulated to. The defense admitted causing some injury. Therefore, the one and only question that the jury had to answer was how much money to award the plaintiff. This would probably take an hour at most. I was wrong. The jury was out for nearly five hours. This was longer than the OJ Simpson jury deliberated. What on earth could they be talking about for so long?
Finally, after spending my entire Friday in the courthouse, there was a verdict. $5,000. A nominal award. One-thirteenth of the amount I was awarded in the pre-suit arbitration. One-tenth of the amount that I was awarded in the court arbitration. $5,000 doesn’t even cover my file costs. My firm lost money. My client got zero. I spent probably 100 hours of my time.
It was obvious to me why they deliberated for so long. There must have been several jurors who did not want to slam the estate of the defendant. The State of New Jersey does not allow me to discuss the deliberations with jurors, so I’ll never know for sure. But I can picture the arguments that happened in that jury room. Something about making this dead person pay did not seem right to them. Hadn’t his family suffered enough? Why were the lady and her shady attorney picking on the dead?
I’ve gotten pretty good at concealing my emotions when in court. When things don’t go my way, I shrug it off and move on. This was different. This was not a case with a liability issue. This was not a case where there was no damage to the car. This was not a case where a tort threshold applied requiring my client to prove a permanent injury. There were no issues with this case.
I walked dejected to the parking lot. My client thanked me and told me I did a great job regardless of the outcome. We embraced. I continued to my car. A juror passed me in her car, rolled her window down and said just one word. “Sorry.” I nodded my head and walked past. When I got home I checked my e-mail and it turned out the same juror who said “Sorry” had e-mailed me. She told me that I did a great job and it was not my fault that the award so low. Given that the rules in New Jersey do not allow me to discuss the deliberations with jurors, I did not respond.
I’m sorry too. I’m sorry I couldn’t get money for my client who was a nice lady and was extremely deserving of it. I’m sorry to myself for having wasted so much of my time. I’m sorry the laws did not allow me to disclose to the jury that I was suing my client’s own insurance company, and was not picking on the deceased. I’m sorry that this no doubt will happen to others. It will happen to people more seriously injured to my client. It will happen to people who have medical bills and are out of work and will rely on this money to survive going forward. I’m sorry that insurance carriers have such a powerful lobbying influence in the legislature. How they have sold the American public on tort reform. How they state that insurance rates are going up because of “frivolous lawsuits.” Civil filings have been consistently down. Some “lawsuit epidemic.” Insurance companies and large corporations have sold the American public on a false narrative and convinced people to give up their right to sue in many areas with the vague promise that insurance rates will go down. Insurance rates remain very high, and people have fewer and fewer rights to file in civil court every year.
Insurance companies need to be held accountable. Most people don’t file lawsuits. Most people don’t like personal injury lawyers. Most people come into court expecting, even hoping, that the plaintiff will be exposed as a liar. However, even these people might be in a situation one day where they are badly hurt and a lawsuit is the only choice. This person will believe it would be different because they would be actually hurt, and the insurance company would know their case was legitimate and pay. And they’d most likely be wrong. That person may find himself put on the stand and called a liar solely because some insurance company wants to protect its money.
The situation I described never would have happened in a state where there was a bad faith statute that was actually enforced. Without one, it’s the insurance companies that rule, not us.
Source: Anna Edney Bloomberg, Charleston Gazette-Mail (
Paulette saw it happen at the playground from several feet away, the panic-inducing moment in 2014 when her 3-year-old son Charlie, who has a life-threatening allergy to milk, grabbed a playmate’s sippy cup and took a gulp. Thankfully, Paulette had the anaphylaxis-stopping EpiPen and was able to quickly use the auto-injector on her son. But when she pulled the needle from his thigh, it was sticking out of the device at an angle instead of being under an orange cover, leaving her unsure whether the lifesaving medicine had been administered. Not wanting to take a chance, Paulette (who requested anonymity to protect her son’s identity) called 911, and Charlie was rushed to a hospital where he remained for several hours until doctors were sure he was all right. “He was OK, but it was nerve-racking to say the least, not knowing if the EpiPen had worked or not,” she said.
Not everyone has been as lucky as Charlie.
EpiPens, which contain the hormone epinephrine (also known as adrenaline), are used to stave off allergic reactions that can in some cases kill. Failure of EpiPens to deploy correctly have been cited in seven deaths this year through mid-September, according to reports by patients and physicians made to the Food and Drug Administration and obtained by Bloomberg News. The FDA received a total of 228 reports of EpiPen or EpiPen Jr. failures during the same time period, according to documents made available as a result of a Freedom of Information Act request. In addition to the deaths, 35 people were hospitalized, according to the reports. Until now, the medical device has been the subject of controversy for a different reason. EpiPen is sold by Mylan NV, a drugmaker legally based in the Netherlands but run from Pennsylvania, that was under fire last year for significantly raising the price of the allergy shot, from about $50 for a single pen to more than $600 for a two-pack. Congress held hearings, government agencies began inquiries, and rival Sanofi sued. The Paris-based competitor claimed Mylan sought “to preserve the monopoly position of their $1 billion crown jewel” by engaging in anti-competitive conduct. Mylan has denied any wrongdoing.
EpiPen and EpiPen Jr. failures, meanwhile, resulted in a recall of some units in March by the company that makes the device for Mylan, Pfizer’s Meridian Medical Technologies. Mylan, which sells the drug-device combo using Meridian’s “pens,” called the defect “extremely rare.”
Reports submitted by users to the FDA, however, show broadening accounts of malfunctions dating as far back as 2014.
In 2012 there were four reports of EpiPen and EpiPen Jr. failures to the FDA, followed by 12 in 2013, according to an agency database. In 2014, those reports jumped more than 400 percent, to 67, according to the reports obtained by Bloomberg. It’s important to note that so-called adverse event complaints don’t confirm that a product caused the incident. At the same time, such reports typically don’t depict the full extent of a problem, given that most people aren’t aware they can submit them in the first place.
Pfizer has previously said consumer complaints aren’t unusual when a product “is frequently administered by non-medically trained individuals.” In an emailed statement Tuesday, the company said it’s “confident in the quality, safety and efficacy of EpiPens manufactured by” its Meridian subsidiary. Pfizer noted, however, that “in the case of EpiPen, adverse events can also be due to epinephrine itself, for a variety of reasons as reflected in the product label.”
Although the reports provided by the FDA don’t explain how the EpiPens failed, FDA investigators who inspected Meridian’s Missouri plant earlier this year said in a warning letter sent in September that epinephrine had in some cases leaked out of the pens. In other cases, the injectors didn’t work properly, the regulator said. “We are not aware of defective EpiPens currently on the market and recommend that consumers use their prescribed epinephrine auto injector,” the FDA said in an emailed statement Tuesday. “We have seen circumstances in which adverse events reports increase once a safety issue is publicized, like a recall. We continue to monitor and investigate the adverse event reports we receive.”
The auto-injecting pen was first developed at a company called Survival Technology, which through a series of deals ended up becoming Meridian. The device was originally used to administer the drug lidocaine for people with irregular heartbeats. Around the same time, the U.S. military approached Survival about using the device to administer treatments for chemical warfare, and NASA astronauts reportedly used a similar approach for nutrition delivery.
Mylan bought the right to sell and market EpiPen in 2007 from Merck KGaA. Meridian has made the auto-injector for Mylan the entire time and has primary manufacturing responsibilities, Mylan spokeswoman Julie Knell said in an email.
The EpiPen’s design has changed in recent years, including tweaks to the orange cap where the needle in Paulette’s device should have been after she injected her son. Mylan said the advancements are crucial to the pen’s safety and functionality, but the changes also protect it from competition by generic device makers until 2025.
In its warning letter, the FDA noted that Meridian staff had said the company initiated a recall of some EpiPens only after government prodding. The agency said inspectors found the device maker had “failed to thoroughly investigate multiple serious component and product failures” for EpiPen products, “including failures associated with patient deaths and severe illness.” The FDA at the time didn’t specify how many were hurt or had died. But even before the recall, which often boosts reports as word spreads, the FDA received 105 complaints of EpiPen failures in 2016. “This is a lifesaving product,” Diana Zuckerman, president of the National Center for Health Research, said in an interview. “If it fails 105 times, that’s significant.” From 2014 to 2017, Meridian received 171 product samples that were the subject of complaints, but didn’t disassemble the “vast majority” of them or offer FDA investigators a reason why, according to the agency’s letter.
Mylan controls about 70 percent of the market for emergency allergy treatments, according to data compiled by Bloomberg in the first quarter of this year. Impax Laboratories Inc.’s lower-cost version, Adrenaclick, accounted for about 18 percent of the market, followed by Auvi-Q with about 12 percent. Almost 4 million prescriptions were dispensed last year for EpiPens, according to data compiled by Bloomberg. Mylan doesn’t break out EpiPen revenue, but its respiratory and allergy sales totaled $1.8 billion in 2016. By comparison, only about 318,000 prescriptions were dispensed for competitor Auvi-Q in 2015, the same year manufacturer Sanofi recalled the product because of a risk of inaccurate dosage. Auvi-Q is now sold by Kaleo Inc.
By David Ferrara Las Vegas Review-Journal
October 17, 2017 – 3:45 pm ( Updated October 17, 2017 – 6:17 pm)
The horrific final moments of a 28-year-old woman’s life at the Route 91 Harvest festival are detailed in a lawsuit filed Tuesday in Los Angeles.
Andrea Castilla “heard gunshots and yelled for her friends and family with her to ‘duck!’” before a bullet struck her in the head, according to the first wrongful death complaint filed in connection with the massacre. “What’s regrettable is that this incident was completely avoidable,” said attorney Richard Bridgford who filed the lawsuit on behalf of the woman’s father, Gus Castilla.
The lawsuit names MGM Resorts International, Live Nation Entertainment, security company Contemporary Services Corp., bump stock maker Slide Fire Solutions LP, and the estate of gunman Stephen Paddock as defendants.
The Oct. 1 massacre left 58 concertgoers dead and injured hundreds of others.
Pointing to Paddock’s 11-minute “reign of terror,” the lawsuit refers to a “packed and enclosed venue,” on which authorities have said he fired using a bump stock device that turned a semi-automatic weapon into a fully automatic weapon. “During this time, the lights at the outdoor venue came on, giving defendant Paddock, who had a bird’s-eye view of the music festival, more visibility,” the lawsuit states. “Gunfire continued to rain down during this time.”
Andrea Castilla’s family and friends carried her toward the edge of the festival grounds, lifting her over a fence and into a good Samaritan’s truck bed, the lawsuit states. “The witnesses with whom we’ve spoken claim that the exits were insufficiently and poorly marked and that there was absolute chaos and really no assistance from any kind of public announcement system,” Bridgford said.
Her sister placed pressure on her wound while she was rushed to Sunrise Hospital and Medical Center, “breathing and humming during the ride.” At the hospital, she was separated from friends and family, who learned the next day that she had died.
The lawsuit alleges negligence against the hotel company, as well as battery, assault and intentional infliction of emotional distress against Paddock’s estate, and gross negligence and product liability against Slide Fire.
Among the allegations in the complaint: MGM failed to surveil people entering and leaving the hotel, failed to notice Paddock taking weapons to his suite, failed to check inside the room for three days after a “do not disturb” sign was hung on the door, and failed to respond to the shooting of Mandalay Bay security officer Jesus Campos. “I cannot fathom that, in an era where casinos have been identified as soft targets for shooting and terrorist occurrences,” Bridgford added, “that the hotel could permit the shooter to access a live concert through breakable glass.”
Through a public relations firm, MGM has released the following statement: “The tragic incident that took place on October 1st was a meticulously planned, evil senseless act. As our company and city work through the healing process, our primary focus and concern is taking actions to support the victims and their families, our guests and employees and cooperating with law enforcement. “We are grateful for all who came to the victims’ aid that evening, including our employees, first responders, the police and citizens who acted in countless ways to assist,” the statement continued. “Out of respect for the victims we are not going to try this case in the public domain and we will give our response through the appropriate legal channels.”
GRAND RAPIDS, MI – Remington Arms blamed a father for the accidental shooting of his daughter who was killed when a rifle discharged in their pickup truck.
Shellsea Lefebre-Schiel, 12, died Sept. 21, 2014, after she was shot in the head while on a hunting trip with her father, Jose Lefebre, on Drummond Island.
Her mother, Michelle Lefebre, filed a $5 million federal lawsuit against the gun maker, which had posted a voluntary recall on its website that said: “Remington has determined that some Model 700 and Model Seven rifles with XMP triggers could, under certain circumstances, unintentionally discharge.”
Shellsea was in the back seat of the four-door pickup. The rifle was tucked between a front-seat passenger’s left leg and interior panel on the console, pointed to the back. The lawsuit contends that a cellphone charger cord apparently moved the safety lever to the fire position.
The rifle discharged while the father was driving the pickup truck. His daughter was struck in the jaw and killed.
Remington Arms, in a motion to dismiss the case, said that blame for the “tragic shooting death” rested with the father. The Protection of Lawful Commerce Act generally protects gun makers and sellers when criminal misuse of an allegedly defective firearm is the cause of such a shooting, Grand Rapids attorney Edward Perdue wrote.
“She was shot and killed as the result of criminal acts committed by her father, Jose Lefebre, who illegally transported a loaded Remington rifle in his motor vehicle with the safety disengaged – in violation of the criminal law – and otherwise handled the rifle in a criminally reckless manner to cause her death,” Perdue wrote.
While the act provides “broad immunity,” there are exceptions, including personal injury or wrongful death that results from a design or manufacturing defect, he said.
“However, the product liability action exception is subject to an exception of its own: when the discharge of the firearm is the result of a ‘volitional act’ that constitutes a ‘criminal offense,’ the criminal act ‘shall be considered the sole proximate cause’ of resulting personal injuries or death,” Perdue wrote.
Lefebre, 47, was charged with involuntary manslaughter, a 15-year felony, and possession of a loaded firearm in a vehicle, a two-year misdemeanor. In a plea agreement, he pleaded guilty to misdemeanor charges of attempted possession of a loaded firearm in a motor vehicle and attempted reckless use of a firearm causing injury or death, records showed.
“In this case, there is no question that Lebrere chose to load the rifle, transport the loaded rifle in the passenger compartment of his truck, and ‘position’ it in his truck so that it pointed toward the rear passenger compartment, where two children sat,” Perdue wrote.
“The unfortunate choices Lefebre made that day were volitional and criminal, and they resulted in Shellsea’s tragic death,” he said.
Lefebre’s attorney, Leonard Siudara, said the father remains distraught.
The lawsuit said that a “defective assembly” of the rifle’s X-Mark Pro, or XMP, fire control system caused the unintended discharge. Lefebre had no way of knowing about the recall unless he checked Remington’s website, his attorney said.
“Remington’s egregious inattention to proper assembly and later inexcusable, willful and wanton delay notifying the public of the defect allowed 2,500,000 defective and dangerous XMP equipped rifles to be sold and used over 8 years of production and Shellsea to suffer a wrongful death,” he said in the lawsuit.
The U.S. Food and Drug Administration today launched a new user-friendly search tool that improves access to data on adverse events associated with drug and biologic products through the FDA’s Adverse Event Reporting System (FAERS). The tool is designed to make it easier for consumers, providers, and researchers to access this information.
“Tools like the FDA Adverse Event Reporting System are critical to the FDA’s ability to help ensure the greatest level of transparency and help patients and providers make safe use of drug and biologic products after they are approved by the FDA,” said FDA Commissioner Scott Gottlieb, M.D. “The FDA is committed to fully informing patients and providers of adverse events reported with medical products and this enhanced portal now provides patients, doctors and others with easier access to the data they are interested in.”
The new dashboard enables users to search for and organize data by criteria such as drug/biological product, age of the patient, type of adverse event, year the adverse event occurred, or within a specific timeframe. In addition to making it easier for consumers to search for adverse events reported with drug or biologic products, the FDA hopes the increased transparency will spur the submission of more detailed and complete reports from consumers, health care professionals and others, by making it easier for people to see other reports that the FDA receives, and search the database for similar observations.
The FDA uses FAERS for surveillance, such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer’s compliance with reporting regulations and responding to outside requests for information. The reports in FAERS are evaluated by clinical reviewers in the FDA’s Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research to monitor the safety of products after they are marketed. If a potential safety concern is identified in FAERS, further evaluation is performed.
“Our focus on safety extends beyond approval,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research. “In fact, our staff spends a lot of time looking at FAERS reports received regarding approved drug and biologic products and these reports can be very valuable components of our safety assessments. By giving people a better understanding of these data, and the associated limitations, we hope the new interface will encourage people to submit more complete reports.”
While the FAERS dashboard now offers stakeholders many more ways of searching for and organizing data on adverse events reported to the FDA for many drug and biologic products, there remain limitations to the data. For example, while FAERS contains reports on adverse events associated with a particular drug or biologic, this does not mean that the drug or biologic caused the adverse event. Importantly, the FAERS data by themselves are not an indicator of the safety profile of the drug or biologic. Patients should still talk to their health care professional if they have any concerns regarding their medications.
The FDA encourages health care professionals and consumers to report adverse events or quality problems experienced with the use of drug and biologic products to the FDA’s MedWatch Adverse Event Reporting program. To do so:
download and complete the form, then submit it via fax at 1-800-FDA-0178.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The Agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
The U.S. Supreme Court on Monday declined to take up an appeal by a Jacksonville-based hospital system about the disclosure of records in medical-malpractice cases.
Southern Baptist Hospital of Florida Inc., which operates as the Baptist Health System in the Jacksonville area, asked the U.S. Supreme Court to hear the case after the Florida Supreme Court ruled that disputed records should be disclosed.
The records fight stemmed from a lawsuit filed against the Baptist system by the family of patient Marie Charles. The lawsuit alleged that negligence in her care caused a severe neurological injury, according to court documents.
The records issue focused on whether hospitals are required to disclose certain records to plaintiffs during medical-malpractice lawsuits, or whether those records are shielded by a federal patient-safety law.
The Florida Supreme Court ruled in the Charles case that the Baptist system was required to turn over the records, pointing to a 2004 state constitutional amendment intended to provide access to what are known in the health-care industry as “adverse medical incident” reports.
The Baptist system, however, argued that at least some of the records were shielded from release by the federal 2005 Patient Safety Act, which allows hospitals to voluntarily submit information about medical errors to what are known as “patient safety organizations” — and offers certain confidentiality protections.
The federal law was aimed, at least in part, at encouraging health providers to submit information that could be analyzed and used to prevent future medical errors.
As is common, the U.S. Supreme Court did not detail its reasons for declining to take up the case.
Name of Product: John Deere D105 lawn tractors and service part transmissions
Hazard: The transmission can fail, posing a crash hazard.
Consumers should immediately stop using the recalled lawn tractors and contact a John Deere dealer for a free repair.
Consumer Contact: Deere & Company at 800- 537-8233 from 8 a.m. to 6 p.m. ET Monday through Friday and Saturday from 9 a.m. to 3 p.m. ET or online at www.deere.com and click on Recalls under the Parts & Service drop-down menu for more information.
Units: About 25,000 tractors and 500 transmissions sold as service parts (in addition, about 1,200 were sold in Canada)
Description: This recall involves John Deere model D105 lawn tractors with serial numbers beginning with 1GXD105, and service transmissions sold by John Deere authorized dealers for use in the D105 lawn tractor. John Deere and the model number are printed on the side of the engine hood. The serial number is located on the rear frame of the machine above the left rear tire. A complete list of serial numbers included in this recall is available at www.JohnDeere.com/D105-Transmission-Recall. If the lawn tractor serial number is not on the firm’s website and the transmission had been replaced from March 2016 through August 2017, consumers should contact their John Deere service dealer to check if the recall applies to their replacement service transmission.
Incidents/Injuries: None reported
Sold at: John Deere dealers, Home Depot and Lowe’s stores nationwide from February 2016 through July 2017 for about $1,500. The service transmissions were sold by John Deere authorized dealers from March 2016 through August 2017 for about $300.
This recall was conducted, voluntarily by the company, under CPSC’s Fast Track Recall process. Fast Track recalls are initiated by firms, who commit to work with CPSC to quickly announce the recall and remedy to protect consumers.